Medical/Pharmaceuticals
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Manag...
2026-06-30 17:37
2005
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together ...
2026-06-30 13:49
1696
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...
2026-06-30 13:36
2197
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2026-06-30 12:00
2219
Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 29, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its ...
2026-06-30 10:06
1967
Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion
TAICHUNG, June 29, 2026 /PRNewswire/ -- Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announcedon June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy for cancer, has successfully cleared review by the Safety Monitoring Committee (SMC). Followin...
2026-06-29 16:47
1622
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-29 09:27
1846
Sisram Medical's China Manufacturing Facility Commences Operations as First Locally Produced Alma Rejuve Rolls Off the Line
Localization strategy advances with strengthened end-to-end capabilities across R&D, manufacturing and commercialization HONG KONG, June 28, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices (EBD), injectables, and...
2026-06-29 09:00
2810
Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA...
2026-06-26 22:30
3904
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
3325
FIT KING Highlights How Different Consumer Routines Are Shaping At-Home Recovery Needs
The wellness brand outlines how its at-home recovery lineup matches active lifestyles, busy workdays, travel routines, first-time users, and everyday home wellness needs NEW YORK, June 25, 2026 /PRNewswire/ -- As recovery continues to move beyond elite athletics and into everyday wellness, FIT K...
2026-06-25 21:00
3147
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
* Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. * This partnership marks sugemalimab's fifth internati...
2026-06-25 17:44
3729
C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework
CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry Adminis...
2026-06-25 11:33
3255
Dimora Medical has joined the NPIAP Corporate Advisory Council as an Honorary Member
NEW YORK, June 24, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, has officially joined the National Pressure Injury Advisory Panel (NPIAP) as a corporate member, marking a new step in its engagement with the global clinical community focused on pre...
2026-06-25 11:24
3482
HKeyBio Debuts HKEY-ExE™ 1.0 to Address Preclinical Bottlenecks in EoE and EgE Drug Development
The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical contract research organization focused on autoimmune an...
2026-06-24 21:18
3119
HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and...
2026-06-24 20:36
2808
Yidu Tech's Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines
DALIAN, China, June 24, 2026 /PRNewswire/ -- On June 23, at the 17th Annual Meeting of the New Champions (Summer Davos 2026) hosted by the World Economic Forum in Dalian, Gong Yingying, Founder and Chairlady of Yidu Tech, participated in the panel discussion "Faster Drugs, Better Access?". She sh...
2026-06-24 17:30
3886
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production camp...
2026-06-24 14:39
3896
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy
SHANGHAI, June 23, 2026 /PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson's disease. Pair...
2026-06-24 14:04
2575
Finetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghai
System delivers filling volume accuracy within ±2–3%, output of 15,600 capsules per hour, and in-line rejection rates below 0.2%, addressing critical dosing consistency requirements for pharmaceutical and nutraceutical manufacturers SHANGHAI, June 24, 2026 /PRNewswire/ -- Finetech Pharmaceutical ...
2026-06-24 13:57
3098
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 307 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 304 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 291 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 290 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 287 media titles]
2026-07-16 17:49
Most Read
PTCL Group Leadership Meets FinVolution at MWC Shanghai 2026 to Explore Credit Technology for Financial Inclusion in Pakistan
2026-07-14 18:32
12043
NYSE Content Update: Madrona Highlights Private Companies Building AI Apps
2026-07-14 21:26
11736
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
11618
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
2026-07-15 12:00
8757